IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.

Immuno-Biological Laboratories Co., Ltd.

4570

JP3921300004

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-21 am EDT			5-day change	1st Jan Change
506 ^JPY	+0.40%		+0.60%	+2.64%

2023	Immuno-Biological Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
2023	An unknown buyer agreed to acquire unknown minority stake in CURED Co., Ltd. from Immuno-Biological Laboratories Co., Ltd.	CI

Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥1.4 billion in funding from Whiz Partners Inc.

December 19, 2016

On December 20, 2016, Immuno-Biological Laboratories Co., Ltd. (JASDAQ:4570) closed the transaction.

Latest news about Immuno-Biological Laboratories Co., Ltd.

Immuno-Biological Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
An unknown buyer agreed to acquire unknown minority stake in CURED Co., Ltd. from Immuno-Biological Laboratories Co., Ltd.	23-02-05	CI
An undisclosed buyer acquired 26.32% stake in Cell Remover Co., Ltd. from Immuno-Biological Laboratories Co., Ltd..	19-12-19	CI
CURED Co., Ltd. announced that it has received ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd.	19-03-28	CI
CURED Co., Ltd. announced that it expects to receive ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd.	19-02-26	CI
Neo Silk Cosmetics Co., Ltd. announced that it has received ¥40 million in funding from Immuno-Biological Laboratories Co., Ltd.	18-11-14	CI
Neo Silk Cosmetics Co., Ltd announced that it expects to receive ¥40 million in funding from Immuno-Biological Laboratories Co., Ltd.	18-11-04	CI
Transgenic Inc. Enters into Joint Research Agreement with Immuno-Biological Laboratories Co. Ltd	17-06-27	CI
Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥1.4 billion in funding from Whiz Partners Inc.	16-12-19	CI
Immuno-Biological Laboratories Co., Ltd. announced that it expects to receive ¥1.39 billion in funding from Whiz Partners Inc.	16-11-30	CI
CURED Co., Ltd. announced that it has received ¥159.6 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd.	16-05-10	CI
CURED announced that it expects to receive ¥159.6 million in funding from Trans Genic Inc. and Immuno-Biological Laboratories Co., Ltd.	16-04-19	CI
Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it has received ¥100 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd.	16-03-30	CI
Hideki Egawa cancelled the acquisition of 79.6 % stake in M Cosmetics Co., Ltd. from Immuno-Biological Laboratories Co., Ltd., Mitsuru Onishi and others.	16-03-27	CI
Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it expects to receive ¥100 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd.	16-03-23	CI
Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥406.31 million in funding from Trans Genic Inc., Merrill Lynch Japan Securities Co., Ltd., Investment Arm.	16-02-29	CI
Immuno-Biological Laboratories Co., Ltd. announced that it expects to receive ¥406.31 million in funding from Trans Genic Inc., Merrill Lynch Japan Securities Co., Ltd., Investment Arm.	16-02-11	CI
Hideki Egawa signed a contract to acquire 79.6 % stake in M Cosmetics Co., Ltd. from Immuno-Biological Laboratories Co., Ltd., Mitsuru Onishi and others for ¥20.6 million.	15-03-27	CI
Xseed High Growth I managed by Japan Asia Investment Co. Ltd. acquired Skylight Biotech Inc.	14-12-30	CI
Astellas Pharma and Immuno-Biological Conclude Collaborative Research Agreement	13-12-31	CI
M Cosmetics Co., Ltd. announced that it expects to receive ¥80 million in funding from Immuno-Biological Laboratories Co., Ltd.	13-09-17	CI
Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥14.70 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm.	13-07-05	CI
Immuno-Biological Laboratories Co., Ltd. completed the acquisition of 41.7% stake in Skylight Biotech Inc.	13-07-01	CI
Immuno-Biological Laboratories Co., Ltd. completed the acquisition of 58.3% stake in Skylight Biotech Inc. from a group of sellers.	13-06-20	CI
Immuno-Biological Laboratories Co., Ltd. announced that it expects to receive ¥14.70 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm.	13-06-14	CI

Chart Immuno-Biological Laboratories Co., Ltd.

Duration

Period

Chart Immuno-Biological Laboratories Co., Ltd.

More charts

Immuno-Biological Laboratories Co., Ltd. is a Japan-based company engaged in the research, development, manufacture and sales of pharmaceutical products and quasi-drugs. The Company operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.

Sector

Pharmaceuticals

Calendar

2024-08-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.	+2.64%	30.08M
ELI LILLY AND COMPANY	+34.35%	705B
NOVO NORDISK A/S	+29.39%	583B
JOHNSON & JOHNSON	-3.49%	364B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	291B
ASTRAZENECA PLC	+14.11%	238B
ROCHE HOLDING AG	-3.03%	210B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+9.21%	169B

Other Pharmaceuticals